US-based device company Nevro has secured market authorisation from the European Union (EU) for its HFX iQ spinal cord ...

Nevro Corp. NVRO reported a loss per share of 41 cents in the third quarter of 2024, narrower than the year-ago quarter’s ...

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the ...

The company announced receiving CE Mark Certification in Europe for its HFX iQ spinal cord stimulation system. Nevro raised ...

Nevro Corp. (NYSE:NVRO) just released its latest quarterly results and things are looking bullish. Results overall were solid, with revenues arriving 4.2% better than analyst forecasts at US$97m.

Nevro shares surged 21% after better-than-expected revenue in its latest quarter. Shares were trading around $6.44. The stock is down 75% on the year.

Nevro Corp (NVRO) has disclosed a new risk, in the Accounting & Financial Operations category. Nevro Corp faces a significant financial risk due to potential declines in its market capitalization, ...

Nevro (NYSE:NVRO) announced today that it received CE mark in Europe for its HFX iQ spinal cord stimulation (SCS) system.

Baird raised the firm’s price target on Nevro (NVRO) to $6 from $5 and keeps a Neutral rating on the shares. The firm said it remains a show-me story as the business transformation remains underway.

Nevro's HFX iQ spinal cord stimulator earned the European Union's CE mark, the company said Nov. 12.

Nevro (NYSE:NVRO) is set to give its latest quarterly earnings report on Monday, 2024-11-11. Here's what investors need to know before the announcement. Analysts estimate that Nevro will report an ...

The Redwood City, California-based company said it had a loss of 41 cents per share. Losses, adjusted for non-recurring gains, came to 51 cents per share. The results exceeded Wall Street expectations ...